Drug Information
Drug (ID: DG00623) and It's Reported Resistant Information
| Name |
Oxcarbazepine
|
||||
|---|---|---|---|---|---|
| Synonyms |
OXCARBAZEPINE; 28721-07-5; Trileptal; Oxcarbamazepine; Oxcarbazepina; Oxcarbazepinum; GP 47680; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; KIN-493; GP-47680; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; UNII-VZI5B1W380; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; MLS000084586; SPN-804; 9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-; CHEMBL1068; SMR000048684; CHEBI:7824; VZI5B1W380; Oxacarbazepine; Timox; MFCD00865307; NSC-758693; NCGC00065934-02; DSSTox_CID_25703; DSSTox_RID_81075; DSSTox_GSID_45703; Oxcarbazepinum [INN-Latin]; Oxcarbazepina [INN-Spanish]; Oxcarbazepime; Epilexter; Epliga; Oxtellar XR; Trileptal (TN); CAS-28721-07-5; SR-01000612612; EINECS 249-188-8; Oxcarbazepin; HSDB 7524; Oxtellar (TN); Oxcarbazepine [USAN:USP:INN:BAN]; OCBZ; Oxcarbazepine solution; Oxcarbazepine- Bio-X; Spectrum_001675; Opera_ID_818; regid866068; Spectrum2_000483; Spectrum3_001669; Spectrum4_000634; Spectrum5_001869; O0363; SCHEMBL35129; BSPBio_003457; KBioGR_001248; KBioSS_002155; cid_34312; MLS000759520; MLS001201742; MLS001424025; MLS006011855; BIDD:GT0078; SPECTRUM1504243; SPBio_000345; GTPL7254; Oxcarbazepine (JAN/USP/INN); ZINC4724; DTXSID0045703; BDBM34179; KBio2_002155; KBio2_004723; KBio2_007291; KBio3_002677; Oxcarbazepine, analytical standard; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; HMS1922H17; HMS2051O04; HMS2090F13; HMS2093E10; HMS2231B12; HMS3369J22; HMS3393O04; HMS3657O11; HMS3713I10; HMS3884K13; Pharmakon1600-01504243; BCP28260; BCP33398; HY-B0114; Tox21_110983; CCG-39509; NSC758693; s1391; STK594696; AKOS005516529; Tox21_110983_1; AC-3483; CS-1869; DB00776; KS-5197; MCULE-9100100302; NC00088; NSC 758693; Oxcarbazepine, >=98% (HPLC), solid; NCGC00065934-03; NCGC00065934-04; NCGC00065934-05; NCGC00065934-06; BO164187; H038; SBI-0206772.P001; GP-47-680; AM20040094; FT-0630543; FT-0673414; SW197468-3; A13943; C07492; D00533; J10384; M06310; AB00393017-12; AB00393017-14; AB00393017_15; AB00393017_16; 721O075; Q176301; SR-01000612612-4; SR-01000612612-6; W-107033; BRD-K04196797-001-12-9; 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide; 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #; Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard; 10,11-Dihydro-10-oxo-5H-dibenzo(Z)[b,f]azepine-5-carboxamide; Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard; 10-Oxo carbazepine; Oxecarb; 10,11-Dihdyro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; Oxcarbazepine, Pharmaceutical Secondary Standard; Certified Reference Material; Oxcarbazepine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Oxcarbazepine-13C6 solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Click to Show/Hide
|
||||
| Indication |
In total 1 Indication(s)
|
||||
| Structure |
|
||||
| Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(2 diseases)
Epilepsy [ICD-11: 8A60]
[1]
Seizures [ICD-11: 8A68]
[2]
|
||||
| Target | Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | SCNBA_HUMAN | [3] | ||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
C15H12N2O2
|
||||
| IsoSMILES |
C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
|
||||
| InChI |
1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
|
||||
| InChIKey |
CTRLABGOLIVAIY-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| ChEBI ID | |||||
| TTD Drug ID | |||||
| VARIDT ID | |||||
| INTEDE ID | |||||
| DrugBank ID | |||||
Type(s) of Resistant Mechanism of This Drug
IDUE: Irregularity in Drug Uptake and Drug Efflux
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-08: Nervous system diseases
Epilepsy [ICD-11: 8A60]
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Irregularity in Drug Uptake and Drug Efflux (IDUE)
|
||||
| Key Molecule: Multidrug resistance protein 1 (ABCB1) | [1] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Disease | Epilepsy [ICD-11: 8A60.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Mechanism Description | In patients with oxcarbazepine (OXC)-resistant epilepsy, the brain tissue expression of ABCB1 mRNA was found to be inversely correlated with brain levels of 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide, the active metabolite of OXC, indicating that Pgp may play a role in the pharmacoresistance to OXC by causing insufficient concentrations of its active metabolite at neuronal targets. | |||
Genetic epileptic syndromes [ICD-11: 8A61]
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
Unusual Activation of Pro-survival Pathway (UAPP)
|
||||
| Key Molecule: Potassium inwardly rectifying channel subfamily J member 10 (KCNJ10) | [3] | |||
| Molecule Alteration | SNP | rs12402969 C+ Genotypes CC+CT |
||
| Sensitive Disease | Genetic generalized epilepsies [ICD-11: 8A61.0] | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Experiment for Molecule Alteration |
Genotyping assay | |||
| Mechanism Description | By analyzing the association between KCNJ10 polymorphisms and anti-epileptic drug efficacy of GGEs we found the frequency of rs12402969 C allele and CC+CT genotypes were higher in GGEs drug responsive patients than that in drug resistant patients | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.